Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics (NYSE: CATX) announced significant developments in its clinical trials program on June 21, 2025. The company has received FDA alignment to open the third dosing cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies.
Additionally, the company presented findings from a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting in New Orleans. This presentation demonstrates the company's progress in developing innovative imaging solutions for neuroendocrine tumor treatment.
The 8-K filing also notes that Perspective Therapeutics has updated its corporate presentation on June 23, 2025, suggesting potential strategic or operational updates to its business model and development pipeline.